The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DXCM | -18.73% | -20.22% | -4.41% | +2,063% |
| S&P | +14.18% | +88.25% | +13.47% | +489% |
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
These healthcare stocks have long-term and profitable growth runways.
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.21B | 21.6% |
| Gross Profit | $747.40M | 25.9% |
| Gross Margin | 61.80% | 2.1% |
| Market Cap | $26.39B | -1.8% |
| Market Cap / Employee | $2.56M | 0.0% |
| Employees | 10.3K | 7.3% |
| Net Income | $283.80M | 110.8% |
| EBITDA | $306.10M | 47.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.84B | 195.5% |
| Accounts Receivable | $1.11B | 10.7% |
| Inventory | 604.1 | 3.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.35B | -47.6% |
| Short Term Debt | $1.23B | 5417.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.40% | -0.1% |
| Return On Invested Capital | 11.36% | 2.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $579.40M | 556.2% |
| Operating Free Cash Flow | $659.90M | 230.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 54.59 | 51.26 | 61.11 | 37.45 | -6.81% |
| Price to Book | 15.35 | 12.69 | 15.10 | 10.26 | -7.06% |
| Price to Sales | 7.84 | 6.71 | 8.28 | 6.07 | -12.72% |
| Price to Tangible Book Value | 16.43 | 13.50 | 15.93 | 10.72 | -8.35% |
| Price to Free Cash Flow TTM | 50.15 | 48.38 | 62.42 | 25.82 | -49.78% |
| Enterprise Value to EBITDA | 128.24 | 143.06 | 128.02 | 87.12 | -34.56% |
| Free Cash Flow Yield | 2.0% | 2.1% | 1.6% | 3.9% | 99.11% |
| Return on Equity | 27.6% | 23.7% | 22.8% | 30.6% | -4.45% |
| Total Debt | $2.59B | $2.58B | $2.58B | $2.58B | -0.60% |
DXCM earnings call for the period ending December 31, 2024.
DXCM earnings call for the period ending September 30, 2024.
DXCM earnings call for the period ending June 30, 2024.
DXCM earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
